stockrowEditas Medicine, Inc.
EDIT Healthcare Biotechnology
Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024.
- Revenue
- +232.3%
- EPS
- +76.2%
- Free cash flow
- +40.7%
Quarter to June 2026, against a year earlier
Follow EDIT
Alert me
Editas Medicine, Inc. (EDIT) EV/Sales
As of 3 November 2026, Editas Medicine, Inc. (EDIT) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from −4.4× (January 2025) to 295× (April 2016); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 9.5× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.7× | — |
| FY2024 | −4.1× | — |
| FY2023 | 6.0× | (55.94%) |
| FY2022 | 13.6× | (73.88%) |
| FY2021 | 52.0× | 26.13% |
| FY2020 | 41.2× | (19.82%) |
| FY2019 | 51.4× | 123.36% |
| FY2018 | 23.0× | (70.97%) |
| FY2017 | 79.3× | 20.31% |
| FY2016 | 65.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.4× | 13.35% |
| Mar 2026 | 3.9× | 132.85% |
| Dec 2025 | 1.7× | (56.80%) |
| Sep 2025 | 3.9× | 279.71% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AVTX Avalo Therapeutics, Inc. compare | −57.2× |
| BLSM BlossomHill Therapeutics, Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| ZURA Zura Bio Limited compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | 0.8× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 2.2× |
| EDIT Editas Medicine, Inc. | 2.8× |
| CCCC C4 Therapeutics, Inc. compare | 5.2× |
| ALT Altimmune, Inc. compare | 1,889× |
| Biotechnology industry median | 9.5× |
| Healthcare sector median | 3.5× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)